A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer

Seunguk Oh, Brad J. Stish, Selwyn M. Vickers, Donald J. Buchsbaum, Ashok Saluja, Daniel A. Vallera

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Biologicals targeting epidermal growth factor (EGF) and interleukin 13 receptors not only react with overexpressed markers on cancer cells but also react with receptors on normal cells. Because we developed novel bispecific ligand-directed toxins synthesized by cloning EGF and interleukin 13 on the same molecule with toxin, our objective was to determine whether we could block normal receptors while still targeting receptors overexpressed on cancer cells, thereby decreasing toxicity while maintaining efficacy. Methods: A method, toxicity blocking (ToxBloc), was developed in which a bolus intraperitoneal dose of recombinant EGF13 (without toxin) was given to mice approximately 15 to 20 minutes before DTEGF13. Experiments were then performed to determine whether the maximal tolerated dose (MTD) was reduced and whether we were still able to eliminate progression of aggressive human, metastatic, pancreatic cancer induced by orthotopic injection (OT) in nude mice. Results: ToxBloc permitted us to safely exceed the DTEGF13 maximal tolerated dose by 15-fold. This approach permitted repetitive high dosing with the bispecific ligand-directed toxin resulting in tumor regression (P < 0.01). Tumor effects were documented using a tumor imaging model in which OT tumor growth was monitored noninvasively in real time. ToxBloc was selective because other bispecific peptides did not block. Conclusions: ToxBloc represents a new method of drug delivery and a potential solution to the problem of toxicity.

Original languageEnglish (US)
Pages (from-to)913-922
Number of pages10
JournalPancreas
Volume39
Issue number6
DOIs
StatePublished - Aug 1 2010
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Ligands
Pharmaceutical Preparations
Neoplasms
Maximum Tolerated Dose
Epidermal Growth Factor
Interleukin-13 Receptors
Injections
Interleukin-13
Nude Mice
Organism Cloning
Peptides
Growth

Keywords

  • EGF
  • IL-13
  • immunotoxin
  • nude mice
  • pancreatic cancer
  • toxicity

ASJC Scopus subject areas

  • Hepatology
  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. / Oh, Seunguk; Stish, Brad J.; Vickers, Selwyn M.; Buchsbaum, Donald J.; Saluja, Ashok; Vallera, Daniel A.

In: Pancreas, Vol. 39, No. 6, 01.08.2010, p. 913-922.

Research output: Contribution to journalArticle

Oh, Seunguk ; Stish, Brad J. ; Vickers, Selwyn M. ; Buchsbaum, Donald J. ; Saluja, Ashok ; Vallera, Daniel A. / A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. In: Pancreas. 2010 ; Vol. 39, No. 6. pp. 913-922.
@article{61b10c54717b40e9a99ebee05f6945bb,
title = "A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer",
abstract = "Objective: Biologicals targeting epidermal growth factor (EGF) and interleukin 13 receptors not only react with overexpressed markers on cancer cells but also react with receptors on normal cells. Because we developed novel bispecific ligand-directed toxins synthesized by cloning EGF and interleukin 13 on the same molecule with toxin, our objective was to determine whether we could block normal receptors while still targeting receptors overexpressed on cancer cells, thereby decreasing toxicity while maintaining efficacy. Methods: A method, toxicity blocking (ToxBloc), was developed in which a bolus intraperitoneal dose of recombinant EGF13 (without toxin) was given to mice approximately 15 to 20 minutes before DTEGF13. Experiments were then performed to determine whether the maximal tolerated dose (MTD) was reduced and whether we were still able to eliminate progression of aggressive human, metastatic, pancreatic cancer induced by orthotopic injection (OT) in nude mice. Results: ToxBloc permitted us to safely exceed the DTEGF13 maximal tolerated dose by 15-fold. This approach permitted repetitive high dosing with the bispecific ligand-directed toxin resulting in tumor regression (P < 0.01). Tumor effects were documented using a tumor imaging model in which OT tumor growth was monitored noninvasively in real time. ToxBloc was selective because other bispecific peptides did not block. Conclusions: ToxBloc represents a new method of drug delivery and a potential solution to the problem of toxicity.",
keywords = "EGF, IL-13, immunotoxin, nude mice, pancreatic cancer, toxicity",
author = "Seunguk Oh and Stish, {Brad J.} and Vickers, {Selwyn M.} and Buchsbaum, {Donald J.} and Ashok Saluja and Vallera, {Daniel A.}",
year = "2010",
month = "8",
day = "1",
doi = "10.1097/MPA.0b013e3181cbd908",
language = "English (US)",
volume = "39",
pages = "913--922",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer

AU - Oh, Seunguk

AU - Stish, Brad J.

AU - Vickers, Selwyn M.

AU - Buchsbaum, Donald J.

AU - Saluja, Ashok

AU - Vallera, Daniel A.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Objective: Biologicals targeting epidermal growth factor (EGF) and interleukin 13 receptors not only react with overexpressed markers on cancer cells but also react with receptors on normal cells. Because we developed novel bispecific ligand-directed toxins synthesized by cloning EGF and interleukin 13 on the same molecule with toxin, our objective was to determine whether we could block normal receptors while still targeting receptors overexpressed on cancer cells, thereby decreasing toxicity while maintaining efficacy. Methods: A method, toxicity blocking (ToxBloc), was developed in which a bolus intraperitoneal dose of recombinant EGF13 (without toxin) was given to mice approximately 15 to 20 minutes before DTEGF13. Experiments were then performed to determine whether the maximal tolerated dose (MTD) was reduced and whether we were still able to eliminate progression of aggressive human, metastatic, pancreatic cancer induced by orthotopic injection (OT) in nude mice. Results: ToxBloc permitted us to safely exceed the DTEGF13 maximal tolerated dose by 15-fold. This approach permitted repetitive high dosing with the bispecific ligand-directed toxin resulting in tumor regression (P < 0.01). Tumor effects were documented using a tumor imaging model in which OT tumor growth was monitored noninvasively in real time. ToxBloc was selective because other bispecific peptides did not block. Conclusions: ToxBloc represents a new method of drug delivery and a potential solution to the problem of toxicity.

AB - Objective: Biologicals targeting epidermal growth factor (EGF) and interleukin 13 receptors not only react with overexpressed markers on cancer cells but also react with receptors on normal cells. Because we developed novel bispecific ligand-directed toxins synthesized by cloning EGF and interleukin 13 on the same molecule with toxin, our objective was to determine whether we could block normal receptors while still targeting receptors overexpressed on cancer cells, thereby decreasing toxicity while maintaining efficacy. Methods: A method, toxicity blocking (ToxBloc), was developed in which a bolus intraperitoneal dose of recombinant EGF13 (without toxin) was given to mice approximately 15 to 20 minutes before DTEGF13. Experiments were then performed to determine whether the maximal tolerated dose (MTD) was reduced and whether we were still able to eliminate progression of aggressive human, metastatic, pancreatic cancer induced by orthotopic injection (OT) in nude mice. Results: ToxBloc permitted us to safely exceed the DTEGF13 maximal tolerated dose by 15-fold. This approach permitted repetitive high dosing with the bispecific ligand-directed toxin resulting in tumor regression (P < 0.01). Tumor effects were documented using a tumor imaging model in which OT tumor growth was monitored noninvasively in real time. ToxBloc was selective because other bispecific peptides did not block. Conclusions: ToxBloc represents a new method of drug delivery and a potential solution to the problem of toxicity.

KW - EGF

KW - IL-13

KW - immunotoxin

KW - nude mice

KW - pancreatic cancer

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=77953403241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953403241&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e3181cbd908

DO - 10.1097/MPA.0b013e3181cbd908

M3 - Article

C2 - 20182395

AN - SCOPUS:77953403241

VL - 39

SP - 913

EP - 922

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 6

ER -